GRACELL BIOTECHNOLOGIES-ADR (GRCL)
US38406L1035 - ADR
We assign a fundamental rating of 2 out of 10 to GRCL. GRCL was compared to 588 industry peers in the Biotechnology industry. The financial health of GRCL is average, but there are quite some concerns on its profitability. GRCL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GRCL has reported negative net income.
In the past year GRCL has reported a negative cash flow from operations.
GRCL had negative earnings in each of the past 5 years.
In the past 5 years GRCL always reported negative operating cash flow.
1.2 Ratios
GRCL has a Return On Assets of -43.64%. This is comparable to the rest of the industry: GRCL outperforms 57.55% of its industry peers.
With a decent Return On Equity value of -52.90%, GRCL is doing good in the industry, outperforming 64.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.64% | ||
| ROE | -52.9% | ||
| ROIC | N/A |
ROA(3y)-29.05%
ROA(5y)-37.01%
ROE(3y)-34.16%
ROE(5y)-644.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GRCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GRCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
GRCL has about the same amout of shares outstanding than it did 1 year ago.
GRCL has a worse debt/assets ratio than last year.
2.2 Solvency
GRCL has an Altman-Z score of 15.19. This indicates that GRCL is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.19, GRCL belongs to the best of the industry, outperforming 88.25% of the companies in the same industry.
A Debt/Equity ratio of 0.12 indicates that GRCL is not too dependend on debt financing.
GRCL has a Debt to Equity ratio of 0.12. This is in the lower half of the industry: GRCL underperforms 67.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 15.19 |
ROIC/WACCN/A
WACC9.48%
2.3 Liquidity
A Current Ratio of 6.44 indicates that GRCL has no problem at all paying its short term obligations.
The Current ratio of GRCL (6.44) is better than 61.74% of its industry peers.
GRCL has a Quick Ratio of 6.44. This indicates that GRCL is financially healthy and has no problem in meeting its short term obligations.
GRCL's Quick ratio of 6.44 is fine compared to the rest of the industry. GRCL outperforms 62.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.44 | ||
| Quick Ratio | 6.44 |
3. Growth
3.1 Past
The earnings per share for GRCL have decreased by -4.00% in the last year.
The Revenue for GRCL has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to decrease by -18.88% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.78%
EPS Next 2Y25.47%
EPS Next 3Y3.89%
EPS Next 5Y-18.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
GRCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.47%
EPS Next 3Y3.89%
5. Dividend
5.1 Amount
No dividends for GRCL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GRACELL BIOTECHNOLOGIES-ADR
NASDAQ:GRCL (2/21/2024, 7:00:01 PM)
After market: 10.25 0 (0%)10.25
+0.01 (+0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap989.87M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.64% | ||
| ROE | -52.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.44 | ||
| Quick Ratio | 6.44 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y29.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y